| Bid | 11.01 |
| Market Cap | 2.61B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.5 |
| PE Ratio (ttm) | -18.37 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 29.98 |
| Volume | 1,744,737 |
| Avg. Volume (20D) | 800,331 |
| Open | 25.75 |
| Previous Close | 25.33 |
| Day's Range | 24.95 - 27.87 |
| 52-Week Range | 9.00 - 38.12 |
| Beta | undefined |
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that t...
Analyst Forecast
According to 6 analyst ratings, the average rating for EWTX stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 81.49% from the latest price.
2 weeks ago · seekingalpha.com
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy DataCompany achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON st...
